Table 3. Association of radiation dose and clinical factors with ≥grade 3 hepatotoxicity.
Eight patients (12.5%) developed ≥grade 3 hepatotoxicity attributable to TARE. Wilcoxon rank-sum tests and Fisher’s exact tests were performed to compare groups, with median (IQR); n (%) presented.
| Characteristic | No hepatotoxicity (n=56) | Hepatotoxicity (n=8) | p-value |
|---|---|---|---|
| Dose to tumor (Gy) | 140.0 (64.0—200.0) | 97.0 (73.0—218.0) | 0.9 |
| Unknown | 5 | 1 | |
| Dose to normal parenchyma (Gy) | 64.0 (34.5—100.0) | 89.0 (68.5—129.5) | 0.068 |
| Unknown | 5 | 1 | |
| Number of extrahepatic metastatic sites | 2.0 (1.0—3.0) | 2.0 (1.0—3.0) | 0.7 |
| TARE device | >0.9 | ||
| Glass microspheres | 37 (88%) | 5 (12%) | |
| Resin micropheres | 19 (86 %) | 3 (14%) | |
| Extent of disease | 0.2 | ||
| Unilobar | 16 (100%) | 0 (0%) | |
| Bilobar | 40 (83%) | 8 (17%) | |
| Number of systemic therapy lines | 8.0 (5.0—11.2) | 7.5 (5.5—14.2) | >0.9 |
| Hormone receptor status | |||
| Estrogen receptor | 0.4 | ||
| ER-negative | 14 (82%) | 3 (18%) | |
| ER-positive | 42 (89%) | 5 (11%) | |
| Progesterone receptor | 0.3 | ||
| PR-negative | 23 (82%) | 5 (18%) | |
| PR-positive | 33 (92%) | 3 (8.3%) | |
| HER2 receptor | >0.9 | ||
| HER2-negative | 46 (87%) | 7 (13%) | |
| HER2-positive | 10 (91%) | 1 (9.1%) | |
| Pre-TARE laboratory values | |||
| Total bilirubin (mg/dL) | 0.5 (0.4—0.7) | 0.9 (0.9—1.1) | 0.013 |
| AST (units/L) | 33.0 (23.0—66.2) | 75.5 (28.5—118.0) | 0.13 |
| ALT (units/L) | 30.0 (18.8—50.2) | 47.0 (35.0—57.5) | 0.3 |
| Platelets (x10^9/L) | 201.5 (159.8—271.0) | 184.5 (134.5—343.2) | 0.7 |
| Percent of normal parenchyma treated | 49.0 (34.0—67.5) | 59.0 (43.5—69.0) | 0.5 |
| Unknown | 5 | 1 | |
| Anticoagulation | 0.044 | ||
| Not anticoagulated | 42 (93%) | 3 (6.7%) | |
| Anticoagulated | 14 (74%) | 5 (26%) |